Sisu Pharma
Chapel Hill, US · Founded 2019 · Delaware corporation
Sisu Pharma develops therapeutics targeting Heat Shock Factor 1 (HSF1), using its HI-LiTe platform to create selective HSF1 degraders for oncology and HSF1 activators for neurodegenerative diseases. Its compounds are aimed at therapy-resistant cancers and other difficult-to-treat diseases.
Founders & leadership
Sisu Pharma was founded in 2019 by Sean E. O'Brien.
SE
Sean E. O'BrieninFounder, Chief Executive Officer
DJ
Dennis J. ThieleinChief Scientific Officer, Member, Scientific Advisory Board
JH
Jiaoti HuangNamed on SEC filing
SO
Sean O'BrienNamed on SEC filing
Board
MS
Michael Serrano-WuBoard director
Reported raises · per SEC filings
Form D private placements$1.7M disclosed across 1 round · 2020
▶$1.7MraisedJul 2020 · 1 investors · PharmaceuticalsRule 506(b)
▶$1.7MraisedJul 2020 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jiaoti HuangExecutive Officer, Director, Promoter
- Dennis ThieleExecutive Officer, Director, Promoter
- Michael Serrano-WuDirector
- Sean O'BrienExecutive Officer, Director, Promoter
- Offering amount
- $4M
- Amount sold
- $1.7M
- First sale
- Jun 2020
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
SiSU Health Group4 shared keywordsSiSU Health operates self-service health check stations that measure cardiometabolic health metrics including blood pressure, BMI, body fat percentage, and diabetes risk for preventive health screening. The company supplies hardware stations to organizations and offers a digital platform to support personalized health improvement.
Uclahealth3 shared keywordsUCLA Health is a major academic health system providing patient care across five hospitals and 290 clinics in Southern California and the Central Coast, alongside research and medical education. The organization conducts pioneering research in oncology, transplantation, neurosurgery, and other specialties, having contributed to the development of numerous FDA-approved treatments.
Companies competing with Sisu Pharma for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Sisu Pharma do?
- Sisu Pharma develops therapeutics targeting Heat Shock Factor 1 (HSF1), using its HI-LiTe platform to create selective HSF1 degraders for oncology and HSF1 activators for neurodegenerative diseases. Its compounds are aimed at therapy-resistant cancers and other difficult-to-treat diseases.
- Who founded Sisu Pharma?
- Sisu Pharma was founded by Sean E. O'Brien in 2019.
- How much funding has Sisu Pharma raised?
- Sisu Pharma has disclosed $1.7M raised across 1 round.
- Where is Sisu Pharma headquartered?
- Sisu Pharma is headquartered in Chapel Hill, US.